Literature DB >> 6331829

Serum C1q levels as a prognostic guide to articular erosions in patients with rheumatoid arthritis.

T Ochi, K Yonemasu, R Iwase, T Sasaki, K Tsuyama, K Ono.   

Abstract

C1q was measured serially by single radial immunodiffusion in 54 rheumatoid arthritis (RA) patients over a period of more than 5 years, and values were correlated with laboratory, radiographic, and clinical findings. The number of joints with erosion (NJE) was determined retrospectively from radiographs of patients who had RA of greater than 7 years duration. In patients with clinically "burned out" RA, C1q levels were not statistically different from those of healthy adults. During the period of active disease, each patient's C1q level remained very constant, irrespective of erythrocyte sedimentation rate, C-reactive protein (CRP) level, or whether the RA was active or in remission. No sustained correlation was found between the C1q level and the other 2 acute phase reactants, but patients with C1q levels of at least 250 micrograms/ml showed a positive CRP over a period of years, in contrast to those with C1q levels below 250 micrograms/ml. Patients with an initial C1q above 250 micrograms/ml had more erosive RA when compared with those having C1q levels below 250 micrograms/ml. These data suggest that active RA can be classified into two subsets by C1q levels, one with persistent inflammation and a high NJE and another without persistent inflammation and with a low NJE.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6331829     DOI: 10.1002/art.1780270807

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  9 in total

1.  Value of joint scintigraphy in the prediction of erosiveness in early rheumatoid arthritis.

Authors:  T T Möttönen; P Hannonen; J Toivanen; A Rekonen; M Oka
Journal:  Ann Rheum Dis       Date:  1988-03       Impact factor: 19.103

2.  Serum levels of RHP and of unbound C1q in rheumatoid arthritis and systemic lupus erythematosus.

Authors:  C L Rosano; N Parhami; K E Hechemy; C Hurwitz
Journal:  Inflammation       Date:  1988-08       Impact factor: 4.092

Review 3.  What happens to patients with rheumatoid arthritis? The long-term outcome of treatment.

Authors:  T D Spector; D L Scott
Journal:  Clin Rheumatol       Date:  1988-09       Impact factor: 2.980

4.  Complement C1s activation in degenerating articular cartilage of rheumatoid arthritis patients: immunohistochemical studies with an active form specific antibody.

Authors:  K Nakagawa; H Sakiyama; T Tsuchida; K Yamaguchi; T Toyoguchi; R Masuda; H Moriya
Journal:  Ann Rheum Dis       Date:  1999-03       Impact factor: 19.103

5.  Association of C1q gene cluster variants with rheumatoid arthritis: a pilot study.

Authors:  Mariya Blagoeva Kosturkova; Galya Mihaylova Mihaylova; Tanya Kirilova Shivacheva; Maria Atanasova Radanova
Journal:  Rheumatol Int       Date:  2022-01-13       Impact factor: 2.631

6.  Prediction of progressive joint damage in patients with rheumatoid arthritis receiving gold or D-penicillamine therapy.

Authors:  P T Dawes; P D Fowler; R Jackson; M Collins; M F Shadforth; R Stone; D L Scott
Journal:  Ann Rheum Dis       Date:  1986-11       Impact factor: 19.103

7.  Serum adiponectin concentrations correlate with severity of rheumatoid arthritis evaluated by extent of joint destruction.

Authors:  Kosuke Ebina; Atsunori Fukuhara; Wataru Ando; Makoto Hirao; Tadashi Koga; Kazuya Oshima; Morihiro Matsuda; Kazuhisa Maeda; Tadashi Nakamura; Takahiro Ochi; Iichiro Shimomura; Hideki Yoshikawa; Jun Hashimoto
Journal:  Clin Rheumatol       Date:  2008-12-16       Impact factor: 2.980

8.  Influence of previous gold treatment and other patient variables on outcome of treatment with disease modifying anti-rheumatic drugs (DMARD) in patients with rheumatoid arthritis.

Authors:  M W Bentzon; I Gad; P Halberg; O Halskov; B K Jacobsen; I Lorenzen; N Morling; A Svejgaard
Journal:  Clin Rheumatol       Date:  1986-01       Impact factor: 2.980

Review 9.  Complement in the Initiation and Evolution of Rheumatoid Arthritis.

Authors:  V Michael Holers; Nirmal K Banda
Journal:  Front Immunol       Date:  2018-05-28       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.